21 Jul 2018 | 11:11 PM
Research Report

Equity Research Report: Master Pick-Lupin

Lupin has a strong pipeline of complex generics in the US, mainly in oral contraceptives and ophthalmics, which it intends to launch in the coming years. This should help to sustain its revenue growth trajectory. While most of this growth is expected to be organic, the company also has plans to grow inorganically, which will help to enter new markets.
29 May 2015 | 06:00 PM

After forming record high at 2115 in early April, 2015, it witnessed profit taking and retraced to the major support zone of 100 days Exponential Moving Average (EMA) on daily chart. It has been consolidating around the same and formed a fresh buying pivot. Short term traders may accumulate it in the given range of 1800-1835 with close below stop loss of 1690 for the target of 2130.